[1]
Jennifer Sims-Mourtada et al. 2018. Dosimetric Characterization of an Abscopal Response in a Patient With Oligometastatic Melanoma Undergoing Concurrent Treatment With Pembrolizumab and Stereotactic Body Radiotherapy (SBRT). Cancer Studies and Molecular Medicine . 4, 1 (Jan. 2018), 1–4. DOI:https://doi.org/10.17140/CSMMOJ-4-121.